Issuer: CureVac / Key word(s): Study28.05.2024 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK Phase 2 study to assess updated formulations for im.
Issuer: CureVac / Key word: Quarter Results
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
23.05.2024 / 13:00.
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza ; Development in Collaboration with GSK finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.